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Abstract
Introduction: Heart failure constitutes a global pandemic affecting at least 26 million globally
(an estimated 5.7 million of which are Americans), and its burden on our healthcare system is
projected to increase.[1] As a result, it is imperative that diagnostics and treatment among
that population be evidence based in order to contain costs and optimize patient outcomes.
Over the last 20 years, thyroid function screening has been recommended for patients upon
initial diagnosis of heart failure by the American College of Cardiology and other professional
organizations. However, it remains unclear whether this recommendation is followed by
practitioners and how much thyroid dysfunction screening uncovers. The aim of this
capstone is to examine the association between thyroid dysfunction and heart failure and
explore a practical example of thyroid function evaluation for patients newly-diagnosed with
that disease.
Objectives: The primary objective of this study is to explore one medical center’s
hospitalizations associated with incident heart failure and determine how often and in which
patients thyroid function is screened (using TSH). A secondary objective was to determine
the amount of thyroid dysfunction discovered through that screening.
Methods: Participants in the current study were sampled from inpatient electronic medical
records for patients at the University of Kentucky Albert B. Chandler Hospital from 20072017. Only first hospitalizations during which heart failure was documented were included in
the study (N = 15900). Logistic regression was used to analyze the association between
patient characteristics and the probability of receiving thyroid function screening during that
hospital stay. Similar analysis was done to explore the association between patient
characteristics and thyroid dysfunction among those screened.
Results: A minority (36.09%) of our patient population had their TSH tested during initial
heart failure admission. In multivariable analysis, longer length of stay (OR: 1.33-2.18), year
of encounter (OR: 1.03, 95% CI: 1.02-1.04), and female sex (OR: 1.29, 95% CI: 1.21-1.38) were
significantly associated with increased odds of patients having their TSH tested. Among those
tested, multivariate analysis revealed that female sex (OR: 1.34, 95% CI: 1.19-2.07) and
longer length of stay (OR: 1.20 for 8-14 days; OR: 1.45 for 22+ days) were associated with
increased odds of thyroid dysfunction (abnormal TSH). African American race [vs white], on
the other hand, was associated with decreased odds of thyroid dysfunction (OR: 0.74, 95%
CI: 0.59-0.93). Age 65+ was also associated with decreased odds of dysfunction (OR: 0.82,
95% CI: 0.67-0.998). Of all patients tested, 28% had thyroid dysfunction. The most common
abnormality detected was high TSH with normal FT4 (11%).
Conclusion: This study suggested that, despite recommendations, only a minority of newly
diagnosed heart failure patients who are hospitalized have their thyroid function screened.
Furthermore, our data hint that thyroid function is not consistently tested on all heart failure
patients but is tested more often in women and in patients with longer hospitalizations.
Among those screened, thyroid dysfunction appeared to be more common than that
reported in the general population but was still a minority of patients. The most common
abnormality detected was subclinical hypothyroidism. We hope that knowing how often
thyroid screening is performed, who specifically is screened, and what testing uncovers may
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lead to more targeted, cost-effective screening in those who would derive the most benefit
from that practice.
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Introduction
This introduction outlines the study’s objectives; provides background
information on heart failure and thyroid dysfunction; offers current knowledge of the
pathophysiology, the mechanisms, and the cardiovascular impact of the different stages
of thyroid dysfunction in heart failure patients; and presents information on the
recommendations for thyroid dysfunction screening.[2]
Study Objectives

The primary objective of this study is to explore one medical center’s incident
heart failure hospitalizations and determine how often and in which patients thyroid
function is screened using Thyroid Stimulating Hormone (TSH). We hypothesize that a
minority of patients will have their thyroid function checked during their initial heart
failure hospitalization, that screening will not be uniform for the entire population
(screening will be more common in patients with certain characteristics), and that thyroid
function testing increases with time. A secondary objective was to determine the amount
of thyroid dysfunction discovered through that screening. We hypothesize that
dysfunction is more common in heart failure patients than in the general population.
Cardiovascular Disease and Heart Failure
1.1 A Brief Introduction to Cardiovascular Disease

Over the last decade, cardiovascular disease (CVD) has become the leading cause
of death worldwide.[3] As more countries progress through the epidemiologic transition
to the final stages to Degenerative/Man-Made and Delayed Degenerative Disease, the
global burden of cardiovascular disease increases. Over 17 million deaths are attributable
6

to CVD each year—nearly a third of all deaths.[4] CVD also confers a heavy burden in
terms of morbidity. CVD was responsible for over 365 million disability-adjusted life-years
(DALYs) lost in 2017 alone.[4] These data represent increases in both absolute numbers
and percentages of DALYs compared with 2015 estimates (355 million DALYs).[4]
1.2 Heart Failure: An Overview

Heart failure is a complex clinical syndrome characterized by impaired heart
function (whether from filling or pumping). Risk factors for heart failure are varied and
include myocarditis, valvular heart disease, tachycardia, diabetes mellitus, structural
heart disease related to congenital heart disease, sleep apnea, excessive drug or alcohol
use, obesity, and CVD (in particular, ischemic heart disease), which confers the highest
risk of heart failure.[5, 6] Heart failure is a global pandemic affecting at least 26 million
globally (an estimated 6.2 million of which are Americans).[1, 7] And the problem is
growing—partly as a result of advances in treatment, demographic change (prevalence
rises exponentially with age and affects 4% to 8% of people older than 65), and improved
survival.[5] While incidence rates have reached a relative plateau, prevalence continues
to rise.[8] In the US alone, it is estimated that heart failure prevalence will increase 46%
from 2012- 2030.[9]
1.3 The Burden of Heart Failure

Unlike some non-communicable conditions that are largely managed in an
outpatient setting (hyperlipidemia, for example), heart failure’s burden is recurrent
(characterized by a relapsing pattern), and the associated healthcare costs fall heavily on
the hospital system.[10] In some areas of the United States, annual hospital readmission
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rates are estimated to be as high as 50%.[11] In 2014 alone, 900,000 hospital discharges
listed heart failure as the primary diagnosis.[7]
Thyroid Dysfunction
2.1 A Brief Introduction to Thyroid Function

The thyroid gland is an endocrine organ tasked with producing hormones that
regulate a multitude of metabolic functions in the human body. Among others, thyroid
hormones play a key role in growth, neuronal development, reproduction, and regulation
of energy metabolism.[12] Consequently, defects in the formation of the thyroid,
production of its hormones, or release of the same can contribute to a variety of adverse
health effects. The thyroid gland secretes two primary hormones, T3
(3,5,3ʹ-triiodothyronine—the more biologically active hormone) and T4
(3,5,3ʹ,5ʹ-tetraiodothyronine; also known as thyroxine).[13] These hormones mediate
their multitude of effects via nuclear hormone receptors.
2.2 Thyroid Dysfunction: Basics

Thyroid dysfunction (a general term that encompasses both deficiency as well as
overabundance of thyroid hormones) is common around the world and can have
potentially devastating health consequences. While deficiency of iodine (an integral
component of thyroid hormones) is reportedly the most common cause of thyroid
disorders, dysfunction remains common in ‘iodine sufficient’ areas such as the United
States.[14]
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2.3 Thyroid Dysfunction: Diagnostic Definitions

Serum Thyroid Stimulating Hormone (TSH, also called serum thyrotropin), the
major regulator of the thyroid, constitutes the single best indicator of its function.[15]
While technically an indirect reflection of thyroid hormone supply (TSH is a stimulating
hormone secreted by the pituitary), it is used as the initial and primary diagnostic
instrument for several reasons. First, TSH is a central component of the negativefeedback system that regulates thyroid function. Second, TSH secretion is exquisitely
sensitive to the plasma concentration of T3 & T4; small changes in serum thyroid function
cause logarithmic amplification in TSH secretion.[16] Even minor fluctuations are
detectable with advanced TSH assays, which are capable of discriminating values as small
as <0.1mU.[16] TSH has a sensitivity of ~98% and specificity of ~92% when used to
confirm clinically suspected thyroid disease by an endocrinologist.[17] However, its
accuracy is difficult to ascertain when it is used to screen asymptomatic persons for
thyroid dysfunction.
While TSH is often the initial thyroid function test used for screening, an abnormal
value often prompts subsequent measurement of T4. Unfortunately, the determination
of a TSH abnormality is not always straightforward. The normal range of serum TSH
concentration varies slightly in different laboratories (sometimes defined this by a
population range), but is now most commonly defined as 0.4 to 4.2 mU/L; This is the
range of TSH prevalence levels in 96% of the disease- and risk-free population.[18] A
complicating factor in the identification of thyroid dysfunction is the relative fluidity of
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what is considered the ‘normal range’ over time. Over the last few decades, the upper
limit of normal has gradually declined from 7.0-10 mU/L to 4.0–5 mU/L.[19]
Thyroid dysfunction can be further divided into that which is ‘subclinical’ versus
‘overt’. Subclinical dysfunction can best be described as an early condition of mild
thyroid hormone excess/deficiency in which thyroid hormones remain within the normal
range. Subclinical hypothyroidism is characterized by a high serum TSH and a normal
serum concentration of free T4 (measured as ‘free’ since the total level can be distorted
by the level of carrier proteins to which thyroid hormones are bound); overt
hypothyroidism has high TSH and a low free T4 serum concentration.[18] Subclinical
hyperthyroidism, on the other hand, is defined by a low TSH and a normal free T4, and
overt hyperthyroidism is described as a low TSH with a high free T4 serum
concentration.[11] These definitions are reflected below in Reference Table 1. Most
endocrinologists recommend repeat testing for those with lab values consistent with
subclinical thyroid dysfunction within 2-3 months since borderline values may not reflect
persistent dysfunction, though the clinical value of this practice is questionable.[19]
Given the significance of TSH for screening, some researchers and clinicians specify levels
of that hormone to further define subclinical dysfunction.[18]
One special combination of abnormal thyroid tests is worth mentioning:
nonthyroidal illness syndrome (also known as euthyroid sick syndrome) is a condition
encountered in patients with acute or chronic systemic illness. The laboratory
parameters that define this syndrome are low T3, low/normal T4 and low/normal TSH.
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This condition may affect 60 to 70% of critically ill patients, and values generally
normalize if the illness resolves (thus hinting at a non-thyroidal etiology).[20]
Reference Table 1: Characterization of Thyroid Dysfunction: Typical Thyroid Function
Tests
Disorder
TSH
Free T4
Overt
¯

Hyperthyroidism
Subacute
Normal
¯
Hyperthyroidism
Overt

¯
Hypothyroidism
Subacute
Normal

Hypothyroidism

2.4 Thyroid Dysfunction: Incidence & Prevalence

The global prevalence and incidence of thyroid dysfunction are difficult to
determine given differences in screening, diagnostic thresholds, assay sensitivities, iodine
nutrition, etc.[12] In general, the overall prevalence of hyperthyroidism and
hypothyroidism ranges from 0.5–4% in iodine-replete communities, and is 5–10 times
higher in women than in men.[21] In the United States, approximately 0.3% suffer from
overt hypothyroidism, but 4.3% have mild or subclinical hypothyroidism.[22]
Hyperthyroidism has a prevalence of 1% to 2% in women and 0.1% to 0.2% in men.[23]
Most of the studies that have explored the epidemiology of thyroid dysfunction
do not distinguish between primary thyroid dysfunction and that which is caused by
other factors. TSH can be depressed, for example, in patients with psychiatric illness,
non-thyroidal illness syndrome, pregnancy, hypothalamic-pituitary disorders, and among
those taking certain medications (glucocorticoids, dopamine, somatostatin analogues,
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amphetamines, dobutamine, bexarotene, bromocriptine).[24] Robust statistics for
primary thyroid dysfunction in the population are unknown.
2.5 Thyroid Dysfunction Screening

The rationale behind thyroid function testing in asymptomatic individuals is early
detection and treatment with the hopes of preventing complications arising from thyroid
imbalance. Specifically, there is hope that screening may prevent morbidity and mortality
from fractures, cancer, or cardiovascular disease. However, widespread screening and
subsequent treatment of thyroid dysfunction can also result in harms due to labeling,
false-positive results, overdiagnosis and overtreatment.
Appropriate use of thyroid function screening has been much debated, and
current recommendations are inconsistent across both countries and medical specialties.
Recently, the United States Preventive Services Task Force (USPSTF) concluded that, for
nonpregnant, asymptomatic adults, “current evidence is insufficient to assess the balance
of benefits and harms of screening for thyroid dysfunction in nonpregnant, asymptomatic
adults.”[25] The American Academy of Family Physicians has endorsed the USPSTF
recommendation, but The American Thyroid Association recommends screening at age
35 years and every 5 years thereafter.[25, 26] The American Association of Clinical
Endocrinologists recommends routine TSH measurement in older patients—age not
specified—especially women.[27] Until the guidelines recently became ‘inactive’, the
American College of Physicians recommended screening in women older than age 50
years with one or more symptoms possibly caused by thyroid disease.[27]
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Although exact estimates of rates in the United States are unknown, screening for
thyroid dysfunction by primary care providers seems to be a common practice in the
developed world.[25] In the United Kingdom, for instance, an estimated 18-25% of adults
receive thyroid function assessed annually.[28]
2.6 Conclusion

Needless to say, the high prevalence of both thyroid dysfunction and heart failure
highlight a need for preventive & therapeutic strategies to reduce morbidity, mortality,
and cost from both of these conditions. The development of such strategies hinges on a
better understanding both of the mechanisms and of the long-term consequences of one
on the other.

Literature Review
This literature review was conducted using Google Scholar and PubMed. The main
key words employed in the literature review were: heart failure, heart failure diagnosis &
management, cardiovascular disease, cardiovascular system, thyroid dysfunction, thyroid
disease, subclinical thyroid dysfunction, thyroid screening, thyroid hormones, thyroidstimulating hormone, hypothyroidism, and hyperthyroidism.
3.1 Historical Investigation of Thyroid Function & Cardiovascular Health

The first documented association between thyroid dysfunction and cardiovascular
health dates back to 1878, when William Greenfield characterized a case of severe
hypothyroidism occurring with vascular disease.[29] Following the development of
radioimmunoassays to estimate TSH in 1965, more quantitative research could be
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conducted. In 1976 Belgian researchers reported higher rates of coronary artery disease,
left ventricular hypertrophy and left ventricular dilation in hypothyroid subjects
compared with a euthyroid group.[13] But over the years, such associations were not
found consistently.[30] And, when a trial of dextrothyroxine (lower activity isomer of T4)
in male survivors of acute myocardial infarction demonstrated higher mortality and
increased arrhythmias, clinicians became wary of the cardiovascular consequences of
hyperthyroidism.[31] Over the past few decades, more detailed studies have
demonstrated that even subtle changes in thyroid hormone concentrations (e.g. those
observed in subclinical hypo or hyperthyroidism) can adversely affect the cardiovascular
system.[13]
3.2 Thyroid Hormones & Cardiovascular Physiology

Many patients with thyroid dysfunction experience some type of cardiovascular
manifestation, and it is believed that the most serious complications of thyroid disease
occur as a result of cardiac involvement.[32] If left untreated, both overtly hypo- and
hyperthyroidism accelerate the onset of symptomatic cardiovascular disease.[13]
Thyroid hormone receptors are present throughout the body, including the myocardium
and vascular tissue, which allow for hormone alterations to affect cardiovascular
physiology such as chronotropy and inotropy.[13] Some mechanisms behind thyroid
hormone’s cardiovascular effects include endothelial dysfunction, dyslipidemia, changes
in blood pressure, and myocardial systolic and diastolic dysfunction.[13]
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3.3 Thyroid Dysfunction & Cardiovascular Health

In hyperthyroid patients, chronotropic effects of thyroid hormones manifest as
tachycardia and increased risk of atrial fibrillation.[33] Other effects of excess thyroid
hormones include increased cardiac output, myocyte hypertrophy, increased left
ventricular mass, arterial stiffness and left atrial size.[24] Components that may
contribute to heart failure include chronotropy, inotropy, and arrhythmogenic activity of
the pulmonary veins.[11]
In contrast, hypothyroid patients demonstrate bradycardia and reduced cardiac
contractility.[33] Hypothyroidism is also associated with reduced cardiac output, heart
rate, and contractility along with increases in peripheral vascular resistance, diastolic
blood pressure, cholesterol levels, and carotid intima-media thickness.[34] Several of
these factors are likely instrumental in accelerating atherosclerosis.[13] Changes in
coagulation parameters observed in hypothyroidism may also contribute to subsequent
cardiovascular disease.[13] The most frequent cardiac abnormality seen with
echocardiogram in individuals with hypothyroidism is diastolic dysfunction owing to
impaired ventricular filling and relaxation.[13]
3.4 Subclinical Thyroid Dysfunction & Cardiovascular Health

Evidence regarding the association between subclinical thyroid dysfunction and
cardiovascular outcomes is conflicting.[13] Some studies document positive associations
with sudden cardiac death[35] and cardiovascular outcomes such as CVD morbidity &
mortality.[11, 13, 24] One study found an increase in cardiovascular disease and death in
hypothyroid patients but not hyperthyroid patients.[21] Others identify an increase in
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mortality in hypothyroidism, but no corresponding increase in cardiovascular events.[35]
To summarize, a multitude of studies have addressed this topic; while many lean towards
the conclusion that subclinical thyroid disease may be associated with cardiovascular
morbidity, no cause and effect can be proven in the absence of mechanistic studies and
randomized clinical trials.[35]
3.5 Thyroid Dysfunction in Heart Failure

According to observational studies, subclinical hypothyroidism and nonthyroidal
illness syndrome are the most frequent thyroid hormone alterations in patients with
heart failure.[36] The latter is particularly common and occurs in an estimated 20-30% of
patients with heart failure.[37] Unfortunately, both subclinical hypothyroidism and
nonthyroidal illness syndrome (also called low T3 syndrome) have been associated with a
poor prognosis.[13]
3.6 Thyroid Screening in Heart Failure Patients

Since the physiological effects of thyroid dysfunction on the cardiovascular
system compromise cardiac function, and since we know thyroid disease may contribute
to heart failure and can be associated with poor prognosis, thyroid function screening
was considered by some to be a standard of care for new onset heart failure until
recently.[11] The American College of Cardiology, jointly with the American Heart
Association, first published guidelines for the evaluation and management of HF in 1995.
In these initial recommendations, TSH was recommended for patients with atrial
fibrillation or sinus rhythm with unexplained heart failure (class I and class II
recommendations, respectively).[38] Subsequent guidelines published in 2001, 2005,
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2009, and 2013 all recommended the measurement of thyroid function tests (especially
TSH) in the initial laboratory evaluation of all patients presenting with heart failure (level
of evidence: C).[39-42] The most recent guidelines published in 2017, however, do not
mention thyroid testing.[43] Still, some highly utilized texts in cardiovascular medicine
continue to recommend this practice.[5]
3.7 Conclusion

The field of cardiology is fortunate to have such an abundance of knowledge on
standard risk factors and secondary preventive measures for both cardiovascular disease
and heart failure. However, to address a disease with such a tremendous burden on
population health, more research is needed to clarify the role of practices such as thyroid
function screening. Knowing how often thyroid screening is performed, who specifically is
screened, and what testing uncovers may lead to more targeted, cost-effective screening
in those who would derive the most benefit from that practice—such knowledge can
help distinguish whether thyroid function screening in this population constitutes a
valuable tool that augments patient care or a misuse of healthcare resources.

Methods
4.1 Setting

The University of Kentucky Albert B. Chandler Hospital is a level 1 trauma, 569bed acute care hospital located in Lexington, KY; it is part of the UK HealthCare
enterprise. During the period of 2007-2017, this institution annually processed more than
30,000 individual inpatient discharges.[44]
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4.2 Study Design & Sampling

This study used a clinical cohort to examine the practice of thyroid dysfunction
screening in adults during their first known hospital admission that included a diagnosis
of heart failure. Data for the current study were limited to the earliest inpatient hospital
stay (also referred to as an inpatient encounter) during which heart failure was
documented as a diagnosis from 2007 through 2017.
In December 2018, inpatient records among heart failure patients from 2004 to
2017 in Sunrise Clinical Manager, the electronic medical record used by the University of
Kentucky inpatient services, were identified. University of Kentucky’s Center for Clinical &
Translational Science Biomedical Informatics Team extracted from their Enterprise Data
Warehouse encounters including an ICD9 or ICD10 diagnosis of heart failure.* A diagnosis
of heart failure during an encounter was identified using the following ICD-9 and ICD-10
code definitions documented at discharge: ICD-9 code of 428.x in any position and ICD-10
code of I50.x in any position. Information obtained included basic demographics and
thyroid function tests. Using the encounter data, the first known inpatient stay
associated with a documented diagnosis of heart failure was determined. Afterwards,
first known heart failure admission encounters were narrowed to those taking place from
2007-2017. This was done for two reasons: first, electronic medical records were
mandated at UK Healthcare in 2004 and it is possible that adjusting to this system makes
early data less reliable; second, it allowed for three years of encounters that could help

The project described was supported by the NIH National Center for Advancing Translational
Sciences through grant number UL1TR001998. The content is solely the responsibility of the
author and does not necessarily represent the official views of the NIH.
*
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determine whether an admission from 2007 on was in fact the first heart failure
hospitalization.[45]
4.3 Variables & Endpoints

All information was obtained from structured data elements and included: age at
the time of encounter, gender, race, ethnicity, and BMI. Additional information included
admission date, discharge date, presence of previously diagnosed heart failure or thyroid
disease, prescription for the most common thyroid medications (see separate appendix
for full list) filled in the past year, and values for the first TSH, Free T3, and Free T4
obtained during the encounter. Previously diagnosed heart failure was defined as a
recorded heart failure ICD-9 or ICD-10 diagnosis (defined above) documented prior to the
encounter—this information included diagnosis codes from inpatient hospital stays as
well as emergency room visits and the EMR used for UK Healthcare’s outpatient
encounters [Ambulatory Electronic Health Record (AEHR)]. In a similar manner,
previously diagnosed thyroid disease was determined by previous documentation of ICD9 (240-246) or ICD-10 codes (E00-E07).
BMI values were categorized according to the common definitions of
underweight, normal weight, overweight, and obese. Patient age was grouped into the
following categories: <45, 45-55, 55-64, 65+ years. These age cutoffs were chosen based
on definitions used in the derivation of premature Coronary Artery Disease and
Atherosclerotic Cardiovascular Disease (ASCVD).[46, 47] For patients with no race or
ethnicity documented, a label of ‘unknown’ was assigned.
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Two outcomes of interest, thyroid function tested and thyroid dysfunction
(among those tested), were used in separate analyses. To assess correlates of thyroid
function testing, dichotomous variables were created to indicate whether or not patients
had TSH performed during the supposed first observed heart failure admission. TSH was
used both because it is the primary recommendation for initial screening and because
every patient whose thyroid function was tested had their TSH evaluated. Normal ranges
for thyroid function tests were chosen based on those used by the UK Healthcare
chemistry laboratory, which reads the tests in question; They are included in Reference
Table 2.
Reference Table 2: Normal Range (Age-based) for Thyroid Function Tests Used in This
Study[48]
Thyroid Function Test
Normal Range
Age range (years)
TSH
18-20yo
0.5-4.3 µIU/mL
21+
0.4-4.2 µIU/mL
Free T4
17+
0.8-1.7 ng/dL
Free T3
All ages
2.2-4.0 pg/mL
4.4 Data Cleaning

Once the data were obtained, encounters without a documented date were
eliminated. In order to restrict the data to inpatient admissions, encounters were limited
to encounters lasting a duration of 1 day or more. Redundant entries were pared down;
any encounters with an identical deidentified encounter ID were merged such that
thyroid function studies were included. When more than one value for a thyroid function
study was available for the initial value, the maximum was used. Encounters were
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eliminated if they did not include a documentation of heart failure during the encounter.
For each deidentified (unique) medical record number, the earliest of these remaining
encounters was selected as the initial heart failure admission. Subsequently, encounters
were eliminated if the patient had a previously documented diagnosis of heart failure or
thyroid disease. Finally, encounters for patients under 18 years old at the time of
encounter were removed.
4.5 Analysis

Overall, a cross-sectional analytic approach was used on the clinical cohort
described. Descriptive statistics were conducted for all encounters and were compared
for both TSH tested vs not and thyroid dysfunction among those tested vs not. Figures
were created to visualize both the proportion of TSH testing per year as well as specific
thyroid function tests ordered for all heart failure encounters.
Logistic regression analyses were performed to determine correlates of the
independent variables listed above and whether TSH was tested (dependent variable).
Thus, odds ratios for the known characteristics were reported. Bivariate analysis of each
individual variable of interest was conducted first. Whether these variables reached
significance determined which were included in the complete model. Finally, the model
was refined with backwards elimination to establish variables in the final model. In this
way, race, ethnicity, and age were eliminated from the model. Sex, year of encounter,
and length of stay were retained for the final model. Models were run with BMI, age,
and length of stay as both categorical (ordinal) and continuous variables. All three had
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higher significance levels when modeled as continuous rather than categorical variables.
Because of this, they were treated as continuous in the final model.
An identical strategy was used to explore any associations between the
characteristics measured and thyroid dysfunction (defined by abnormal TSH). The
dependent variable was dichotomized as TSH normal (within the normal range) vs
abnormal. Logistic regression was used to estimate odds ratios for thyroid dysfunction
among those tested for each characteristic measured. Whether these variables reached
significance determined which were included in the complete model. This model was
refined with backwards elimination to establish variables in the final model. The final
dependent variables in the final model were: sex, length of stay, age 65 years +, and
black/African American race (vs white).
All analyses were conducted using SAS software, version 9.4 (SAS Institute; Cary,
NC, USA).

Results
5.1 Final Data Set

Data for 841032 inpatient encounters were collected from 22491 unique patients
who had heart failure documented at some point between 2004-2018. Exclusion criteria
were applied to obtain a final data set consisting of 15900 encounters from unique
patients occurring 2007-2017. These encounters met the criteria of initial heart failure
encounters in adults with no known thyroid dysfunction. See Figure 1 for more details on
specific exclusions.
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Figure 1. Final Data Set Selection Process
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5.2 Overall Encounter Characteristics

Tables 1 summarizes patient demographics in all patients encountered. The
patients were 55% male and 45% female and mean age was 64.8 years (range 18-104).
The number of participants was highest in the age group 65+ (52.74%), and lowest in the
group <45 (9.26%). White participants dominated this study (constituting 89.58%);
black/African American was second most prevalent race (7.43%), with very few others.
Race was unreported or not provided for 2.3% of encounters. The majority (77.75%) of
patients were non-Hispanic/Latino and 21.52% were unknown. Only 0.73% were
Hispanic/Latino. Average BMI was 37.42kg/m2, with the highest percentage of patients
having a BMI over 30 kg/m2 (41.74%). Average length of stay was 11.17 days, but most
patients were hospitalized for 1-7 days (56.92%). The proportion of encounters during
which TSH was tested increased over the study period from 6.18% in 2007 to 13.42% in
2017. Prevalence of thyroid screening in our population is presented in Figure 2. Over
the study period, 36.09% of newly diagnosed heart failure patients had their TSH checked
during hospitalization. Further information regarding of specific tests ordered during the
inpatient encounters is presented in Figure 3.
5.3 Thyroid Function Screening

Table 2 reports demographics in patients with thyroid function tested vs not.
Table 2 also includes results from bivariate logistic regression analysis, including
unadjusted odds ratios, 95% confidence intervals and p-values to provide associations
among covariates to thyroid function being tested. Thyroid function testing was
significantly associated with female sex (p=<.01), length of stay (p=<.01) and year of
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encounter (p=<.01). Race, ethnicity, and age were not significantly associated with
thyroid function testing. Table 4 presents the results from multivariable logistic
regression model for thyroid function testing. Adjusting for other covariates in the model,
female sex, length of stay, and year of encounter remained significant (all p=<.01) in
association with thyroid testing. Female patients had 1.29 times the odds of having their
TSH tested in comparison to males. With each progressive year, the odds of TSH testing
in this population increased by 0.03. Finally, the odds of testing increased with each
subsequent length of stay interval.
5.4 Thyroid Dysfunction

Additionally, results are presented for the analysis of tested patients and whether
they had thyroid dysfunction. Table 3 compares and contrasts demographics between
tested patients who were found to have dysfunction vs not. Results of bivariate logistic
regression are also included. Patients who underwent TSH testing were mostly white
(89.00%) non-Hispanic/Latino (77.59%), slightly more male (51.19%) with a mean age of
65.08 years. There were no biracial subjects in this group. Mean BMI was 36.13 kg/m2
and mean length of stay was 13.71 days. Bivariate analysis using the created variable
‘dysfunction’ suggested that female sex, African American/black and unreported race,
and length of stay 8-14 or 22+ days were associated with increased thyroid dysfunction
(p=<.01, .01, .04, .01, <.01 respectively). Age 65+ was associated with decreased odds of
dysfunction (p=.0459). Year of encounter, BMI, other races, & ethnicity did not show a
significant association with thyroid dysfunction.
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Table 5 presents results from multivariate logistic regression model for thyroid
dysfunction, including the variables of female sex, length of stay (8-14 & 22+ days),
black/African American race, unreported/refused race, and age. Adjusting for other
covariates, patients who were female (OR 1.34, p=<.01), or whose hospital stay lasted 814 days or 22+ days (OR 1.2 and 1.45 respectively) had increased odds of thyroid
dysfunction. The designation of unreported/refused for race lost its significance. In
analysis adjusted for sex and length of stay, Black/African American patients, had 0.74
(p=0.01) times the odds of thyroid dysfunction when compared to whites among patients
with an incident heart failure hospitalization. Age over 65 was associated with decreased
risk of thyroid dysfunction (OR: 0.82, p=0.048).

Discussion
6.1 Introduction

To my knowledge, this is the first study to examine frequency of thyroid function
testing in adult patients admitted to the hospital with heart failure, and the first to
examine the characteristics of those tested vs not. The purpose of this study was to
identify the frequency with which adults initially admitted for heart failure had their
thyroid function checked at the University of Kentucky Albert Chandler hospital over the
period 2007-2017 and to describe the frequency of thyroid dysfunction observed in those
patients.
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6.2 Frequency of Thyroid Function Screening

Despite the recommendations to screen for thyroid dysfunction in this patient
population, a minority of patients (36.09%) had their TSH tested in this study.
Unfortunately, no studies have previously examined thyroid function screening in
patients with heart failure. So, it is unclear how these results would compare to a
broader population. It may be that many clinicians are carefully considering the lack of
evidence behind this recommendation (level C) and have largely chosen not to universally
screen initial heart failure patients. In conjunction with this, providers may be taking into
account other patient risk factors for heart failure. In a patient with multiple
comorbidities, they determine that likelihood heart failure is due to thyroid dysfunction is
low. For patients that tend to receive most of their care within the UK Healthcare system,
practitioners may deem screening unnecessary if they have been tested relatively
recently.
Longer hospital stays were associated with increased odds of testing. (ORs: 1.33,
1.69, 2.18 for 2, 3, and more than 4 weeks respectively). It is reasonable to (on average)
consider a longer length of stay indicative of a more severe illness. In such patients, it is
often practical to ensure no easily treatable contributing factors like thyroid dysfunction
can be addressed while the patient is in the hospital. A longer length of stay also allows
for more opportunities for different providers to order thyroid function studies.
While the magnitude of the association is not particularly strong (OR: 1.03, 95%
CI: 1.02-1.04), there was a significant increase in testing frequency with each progressive
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year. This may reflect greater availability of tests, increased ease of ordering, and/or
better resources with regard to informing providers of ACC recommendations.
Controlling for length of stay and year, female patients had 1.29 times the odds of
having their thyroid function screened versus males (95% CI: 1.21-1.38). We do know
that females are more likely to suffer from thyroid dysfunction than their male
counterparts, and this alone may account for more thyroid function testing among
females.[30] In other words, providers that recognize gender as a risk factor may
consider testing to be of higher value in this population. However, it is also true that
women are underdiagnosed and undertreated with regard to cardiovascular disease, and
are less likely to receive preventive treatment and guidance than are men at a similar
ASCVD risk.[49-51] Because practitioners are less likely to recognize cardiovascular
disease in women (strongest risk factor for heart failure), they may be searching for an
alternate etiology.
6.3 Thyroid Dysfunction Among Screened Patients

Among the patients screened for thyroid dysfunction, most patients had a TSH
(72%) within the normal range. In total, 28% of those tested revealed some sort of
thyroid dysfunction. A study that included hospitalized patients aged 65 or older
demonstrated 17.4% thyroid dysfunction.[52] Patients hospitalized with COPD
exacerbation had 20% abnormal TSH.[53] In patient screened in the CORONA trial (which
sought to examine the effect of low-dose rosuvastatin on survival in heart failure), 8.7%
were discovered to have thyroid dysfunction using a broader normal range for TSH.[54]
Thus, our study suggests thyroid dysfunction may be more prevalent among our group of
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patients initially diagnosed with heart failure as compared with other hospitalized
groups—even other groups diagnosed with heart failure.
The most common thyroid dysfunction among those tested was high TSH with
normal FT4 (11%). This is concordant with many observational studies which have shown
this pattern (consistent with subclinical hypothyroidism).[36] Nonthyroidal illness
syndrome, another common thyroid hormone disturbance in ill patients, could not be
adequately evaluated since the TSH values may be normal in this condition and T3 was
rarely measured.
Among screened patients, multivariate analysis revealed that female sex (OR:
1.33, 95% CI: 1.18-1.49) was associated with increased odds of thyroid dysfunction
(abnormal TSH). This is in agreement with studies that have consistently found
prevalence of thyroid dysfunction is much higher in females than males in the general
population.[55, 56]
To some extent, increasing length of stay was also associated with increased odds
of thyroid dysfunction (8-14 days and 22+ days OR: 1.20 & 1.45 respectively).
Interestingly, the 15-21 day range did not reach significance. While dysfunction
increasing with time could be secondary to longstanding illness, disease severity was not
ascertained in this study. Since any differential of greater comorbidity among longer
hospitalization is unknown, this is highly speculative. It is unclear why the middle range
did not reach significance.
African American race [vs white], was associated with decreased odds of thyroid
dysfunction (OR: 0.74, 95% CI: 0.59-0.93). In a large prospective study in Brazil, Olmos, et
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al. demonstrated that African Americans had less thyroid dysfunction overall, but that
this was mainly a result of less overt hypothyroidism (OR = 0.76) despite increased overt
hyperthyroidism (OR = 1.82).[57] While this study did not examine the particular types of
thyroid dysfunction, it is concordant with this and other studies that conclude African
Americans have a lower prevalence of thyroid dysfunction as a whole.[17, 58]
Age was included in the final model since it is consistently associated with thyroid
dysfunction in the literature.[55, 59] Multiple studies have shown the incidence and
prevalence of both hypo and hyperthyroidism increased with age.[60, 61]
Hypothyroidism, for example, seems to climb with each decade—it ranged from 4 to 21%
in women and 3 to 16% in men.[62] In our study, only the age range of 65+ showed an
association with thyroid dysfunction—and this was a negative association. This is
puzzling, as we would expect the opposite. It is possible that the selection bias inherent
in studying a disease more common in the elderly has made age as a covariate less
reliable.
While race ‘unreported’ [vs white] was initially associated with increased odds of
thyroid dysfunction, this variable did not maintain significance in the final model (p=.06).
6.4 Limitations: population, characteristics/measurements, analysis

Thyroid function screening in newly diagnosed heart failure patients is an
understudied aspect of heart failure management. Though this study is unique in its
examination of this issue, it is not without limitations. Encounters were restricted to
patients admitted to a single hospital within the UK Healthcare setting. The study
therefore relied on a small sample of heart failure patients—and ones that are unique to
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the University of Kentucky. It is only by considering encounters across the whole
spectrum of acute and chronic care that the full picture of practice and prevalence can be
captured. Heart failure may be both diagnosed and treated solely in an outpatient
setting, and these cases are not accounted for in this analysis. In two studies, the
proportion of heart failure diagnoses occurring in an outpatient setting ranged from 31 to
42%.[63] When emergency department visits are included (for patients diagnosed but
not admitted), the proportion may be as high as 52%.[64] This study does not capture
this ‘outpatient’ subset of heart failure patients.
Misclassification may have occurred since we have very limited data on patients,
and a validated ascertainment protocol was not utilized. As a result, heart failure
ascertainment, in particular, may have been very inaccurate. Since any diagnostic
position was used to define a heart failure encounter, a substantial proportion of the
primary reason for hospitalization may not have been heart failure-related. And, since
this data only covers a single EMR, any outside medical care is unaccounted for. We may
have, for instance, identified an encounter as an initial heart failure encounter when that
individual simply has chronic heart failure but just recently started receiving care at UK.
There are innumerable potential confounding factors that this study was unable
to account for. For example, it was not possible to obtain reliable data on which provider
ordered the thyroid function tests. It is entirely possible that provider preference is the
dominant determinant of thyroid function testing. And, while odds ratios suggest that
differences in patient characteristics between tested and not-tested patients were small,
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we did not have comprehensive data on comorbidities, family history, or vital signs (just
to name a few).
It should be stressed that what constitutes an abnormal TSH level is uncertain.
Laboratories use reference intervals based on statistical distribution across a population
rather than based on clinical outcomes, and different TSH cutoffs are used to define
subclinical thyroid dysfunction in particular.[25] This study has defined undifferentiated
thyroid dysfunction using these parameters, and therefore cannot comment on its
relation to increased risk of adverse outcomes, or on more specific types of thyroid
dysfunction. TSH secretion does fluctuate during the day, with peak values in the early
morning and a nadir in the afternoon.[18] As the more common lab draws obtained in
the hospital do occur early in the morning, it is possible that the study has effectively
over-diagnosed some patients. It is also unknown how many (if any) patients were tested
based on symptoms rather than blanket screening.
6.5 Further Comments

Despite the published recommendation to obtain thyroid function tests
(especially TSH) since 1995, this study demonstrated that at UK Albert Chandler Hospital,
obtaining TSH is not very common among HF patients, though testing in this specific
population may have slightly increased over the study period. While no formal
explanation was offered, the failure to maintain this recommendation in a 2017 update
may reflect doubt as to its cost-efficacy and value to patient care.
Proponents of screening claim that erring on the side of caution to detect a
treatable condition is the prudent choice—particularly since overt thyroid dysfunction is
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associated with adverse sequelae such as increased bone turnover, osteoporosis, and
fractures.[24] Furthermore, studies have shown that in-hospital TSH values are highly
concordant with ambulatory values in patients over 65 (our main heart failure
population), and thus may not need to be repeated prior to initializing treatment.[52]
While there is some evidence from prospective studies that even subclinical
hypothyroidism and congestive heart failure are correlated, questions remain: which
comes first, when do we treat, does screening improve patient outcomes, and is it cost
effective.[65]
At this time, the benefit of thyroid function testing both in the general population
and in heart failure patients is unknown. Furthermore, epidemiological evidence
supporting treatment of subclinical dysfunction especially is limited and results are
mixed.[25]
Not only are ‘normal ranges’ of TSH unknown, currently there is a lack of
consensus on when treatment for thyroid dysfunction (subclinical especially) is indicated.
[25] This is true of the general populace as well as those hospitalized with heart failure.
So to a certain extent screening is of limited value. Finally, it is important to think of all
possible consequences of screening. For example, a large magnitude of overdiagnosis
and overtreatment likely follows from screening asymptomatic individuals. USPSTF aptly
states that “overdiagnosis leads to psychological consequences and unnecessary
treatment…it should be avoided in disease prevention and health promotion.”[25]

33

6.6 Next Steps

More research is needed in this area. Specifically, studies need to evaluate harms
and benefits of thyroid screening in heart failure patients in order to establish whether
the practice confers a health benefit. Studies are also needed to explore what TSH values
should serve as clinically meaningful cutoffs for diagnosis and treatment. Finally, we need
to investigate long-term outcomes of thyroid dysfunction in heart failure patients.
6.7 Conclusions

Despite progress made in the management of heart failure, this syndrome is still
associated with poor clinical outcomes including a high risk of mortality.[11] Its burden
on the healthcare system is high—heart failure was responsible for an estimated 31
billion dollars of health care expenditure in 2012 (not counting indirect costs & loss of
productivity).[1] Its costs are projected to increase by 46% by 2030. Nearly 80% of the
projected expenses are attributable to increased hospitalizations.[10] In order to reduce
hospitalizations and related costs, management strategies should be based on highquality evidence. Gaining better understanding of all factors that contribute to heart
failure can help formulate interventions aimed at decreasing incidence, prevalence, and
the burden of heart failure on our healthcare system. In the same vein, it is important to
recognize which steps can be taken to reduce costs during heart failure hospitalizations
and avoid harms of interventions. Thyroid function screening is a practice that is
commonly performed in heart failure patients despite lacking evidence on improved
outcomes. More research is needed to determine how screening is used and what
population it is most likely to benefit.
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This study explored the use of thyroid function screening in newly diagnosed
heart failure patients hospitalized at the University of Kentucky Albert B. Chandler Hospital
from 2007-2017. The results suggest that, despite recommendations, only a minority of
newly diagnosed heart failure patients who are hospitalized have their thyroid function
screened. Furthermore, our data hint that thyroid function is not consistently tested on all
heart failure patients but is tested more often in women and patients with longer
hospitalizations. Screening also increased over time. Among those screened, thyroid
dysfunction appeared to be more common than that reported in the general population but
was still a minority of patients. The most common abnormality detected was subclinical
hypothyroidism. We hope that knowing how often thyroid screening is performed, who
specifically is screened, and what testing uncovers may lead to more targeted, cost-effective
screening in those who would derive the most benefit from that practice.

Further studies should investigate the role of thyroid dysfunction across the
natural history of cardiovascular disease in general (and heart failure specifically) to gain
a better understanding of the underlying mechanisms. Not only are studies needed to
clarify the benefits and harms of screening in this population, but randomized controlled
trials should be conducted to demonstrate benefit of treatment and establish an
evidence-based threshold for treatment.
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Appendix

Table 1. Characteristics of Adult Patients During First Known Hospital Admission with
Documentation of Heart Failure at the University of Kentucky Albert B. Chandler Hospital
from 2007-2017
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Table 2. Bivariate Analysis of Patient Encounter Characteristics and Thyroid Screening for
Adult Patients During First Known Hospital Admission with Documentation of Heart
Failure at the University of Kentucky Albert B. Chandler Hospital from 2007-2017
Characteristic
TOTAL N=15900

Sex
Male
Female
Race
White
Black/African American
Asian
Spanish American
American Indian/Alaskan
Middle Eastern
Hawaiian/Pacific Islander
Bi-racial
Unreported/Refused
Ethnicity
Non-Hispanic/Latino
Hispanic/Latino
Unreported/Refused
Age at admission
<45
45-54
55-64
65+
BMI
< 18.5
18.5–24.9
25-29.9
30+
Unknown
Length of stay (days)
1-7 days
8-14 days
15-21 days
22+
Year of encounter
2007
2008
2009
2010
2011
2012
2013
2014

Thyroid
function not
tested
N=10162
(63.91%)
5795 (57.03)
4367 (42.97)
9136 (89.90)
724 (7.12)
20 (0.20)
24 (0.24)
9 (0.09)
9 (0.09)
4 (0.04)
3 (0.03)
228 (2.24)
7910 (77.84)
65 (0.64)
2187 (21.52)
931 (9.16)
1452 (14.29)
2476 (24.37)
5303 (52.18)
381 (3.75)
2282 (22.46)
2481 (24.41)
4222 (41.55)
796 (7.83)
6223 (61.24)
2113 (20.79)
801 (7.88)
1025 (10.09)
670 (6.59)
593 (5.84)
669 (6.58)
816 (8.03)
874 (8.60)
804 (7.91)
915 (9.00)
1118 (11.00)

Thyroid
function
tested
N=5738
(36.09%)
2937 (51.19)
2801 (48.81)
5107 (89.00)
457 (7.96)
20 (0.35)
14 (0.24)
5 (0.09)
1 (0.02)
2 (0.03)
0 (0.00)
132 (2.30)
4452 (77.59)
51 (0.89)
1235 (21.52)
541 (9.43)
750 (13.07)
1364 (23.77)
3083 (53.73)
205 (3.57)
1297 (22.60)
1436 (25.03)
2414 (42.07)
386 (6.73)
2827 (49.27)
1278(22.27)
616 (10.74)
1017 (17.72)
313 (5.45)
321 (5.59)
319 (5.56)
418 (7.28)
552 (9.62)
485 (8.45)
457 (7.96)
529 (9.22)

Crude
Odds
Ratio

95% CI

p- value

Ref
1.27
Ref
1.13
1.79
1.04
0.99
0.20
0.89
*
1.01
Ref
1.39
1.00
Ref
0.80
0.95
1.00
Ref
1.06
0.98
1.06
0.90
Ref
1.33
1.69
2.18
1.03

Ref
1.19,1.35
Ref
1.00,1.28
0.96,3.33
0.54,2.02
0.33,2.97
0.03,1.57
0.16,4.89

Ref
<.0001
Ref
0.051
0.07
0.90
0.99
0.13
0.90
*
0.90
Ref
0.08
0.93
Ref
0.09
0.40
0.99
Ref
0.56
0.43
0.50
0.33
Ref
<.0001
<.0001
<.0001
<.0001

*

0.82,1.26
Ref
0.96,2.02
0.93,1.09
Ref
0.77,1.02
0.84,1.07
0.89,1.12
Ref
0.88,1.27
0.90,1.29
0.89,1.27
0.73,1.11
Ref
1.22,1.45
1.51,1.90
1.98,2.41
1.02,1.04
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2015
2016
2017

1225 (12.05)
1222 (12.03)
1256 (12.36)

658 (11.47)
808 (14.08)
878 (15.30)

*Numbers too small to estimate a stable OR
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Table 3. Bivariate Analysis of Adult Patients Screened for Thyroid Dysfunction During
First Known Hospital Admission with Documentation of Heart Failure at the University of
Kentucky Albert B. Chandler Hospital from 2007-2017
Characteristic

No Thyroid
Dysfunction

Thyroid
Dysfunction

TOTAL N=5738
Sex
Male
Female

N=4133 (72.03%)

N= 1605 (27.97%)

2197 (53.16)
1936 (46.84)

740 (46.11)
865 (53.89)

Crude
Odds
Ratio
Ref
1.33

Race
White
Black/African American
Asian
Spanish American
American Indian/Alaskan
Middle Eastern
Hawaiian/Pacific Islander
Bi-racial
Unreported/Refused

3662 (88.60)
354 (8.57)
18 (0.44)
9 (0.22)
5 (0.21)
0 (0)
1 (0.02)
0 (0)
84 (2.03)

1445 (90.03)
103 (6.42)
2 (0.12)
5 (0.31)
0 (0)
1 (0.06)
1 (0.06)
0 (0)
48 (2.99)

Ethnicity
Non-Hispanic/Latino
Hispanic/Latino
Unreported/Refused
Age at admission
<45
45-54
55-64
65+
BMI
< 18.5
18.5–24.9
25-29.9
30+
Unknown
Length of stay (days)
1-7 days
8-14 days
15-21 days
22+

3230 (78.15)
40 (0.97)
863 (20.88)
371 (8.98)
544 (13.16)
977 (23.64)
2241 (54.22)
140 (3.39)
934 (22.60)
1052 (25.45)
1745 (42.22)
262 (6.34)
2110 (51.05)
905 (21.90)
439 (10.62)
679 (16.43)

Year of encounter
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017

221 (5.35
237 (5.73)
220 (5.32)
323 (7.82)
413 (9.99)
350 (8.47)
331 (8.01)
368 (8.90)
469 (11.35)
567 (13.72)
634 (15.34)

95% CI

p- value

Ref
1.18,1.49

Ref
<.0001

Ref
0.74
0.28
1.41
*
*
2.53
*
1.45

Ref
0.59,0.93
0.07,1.22
0.47,4.21
*
*
0.16,40.54
*
1.01,2.08

Ref
0.01
0.09
0.54
*
*
0.51
*
0.04

1222 (76.14)
11 (0.69)
372 (23.18)
170 (10.59)
206 (12.83)
387 (24.11)
842 (52.46)
65 (4.05)
363 (22.60)
384 (23.93)
669 (41.68)
124 (7.73)
717 (44.67)
373 (23.24)
177 (11.03)
338 (21.06)

Ref
0.73
1.14
Ref
0.83
0.86
0.82
Ref
0.81
0.77
0.81
0.97
Ref
1.21
1.187
1.47

Ref
0.37,1.42
1.00,1.31
Ref
0.65,1.05
0.70,1.07
0.67,1.00
Ref
0.59,1.13
0.55,1.06
0.59,1.10
0.67,1.41
Ref
1.05,1.41
0.98,1.44
1.25,1.71

Ref
0.35
0.06
Ref
0.12
0.19
0.0495
Ref
0.22
0.11
0.18
0.88
Ref
0.01
0..08
<.0001

92 (5.73)
84 (5.23)
99 (6.17)
95 (5.92)
139 (8.66)
135 (8.41)
126 (7.85)
161 (10.03)
189 (11.78)
241 (15.02)
244 (15.20)

1.01

0.992,1.030

0.25

*Numbers too small to estimate stable OR

39

Table 4. Logistic Regression of Patient Characteristics for Thyroid Function Screening
Among Adult Patients During First Known Hospital Admission with Documentation of
Heart Failure at the University of Kentucky Albert B. Chandler Hospital from 2007-2017
Characteristic
Sex
Male
Female
Year of Encounter
Length of Stay (days)
1-7 days
8-14 days
15-21 days
22+

Adjusted OR

95% CI

p-value

Ref
1.29
1.03
Ref
1.32
1.69
2.21

Ref
1.22,1.39
1.02,1.04
Ref
1.22,1.44
1.51,1.89
2.01,2.44

Ref
<.0001
<.0001
Ref
<.0001
<.0001
<.0001
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Table 5. Logistic Regression of Patient Characteristics for Thyroid Dysfunction Among
Adult Patients Screened for Thyroid Dysfunction During First Known Hospital Admission
with Documentation of Heart Failure at the University of Kentucky Albert B. Chandler
Hospital from 2007-2017
Characteristic
Sex
Male
Female
Length of Stay (days)
1-7 days
8-14 days
15-21 days
22+
Race
White
Black/African American
Unreported/Refused
Age at admission
<45
45-54
55-64
65+

Adjusted OR

95% CI

p-value

Ref
1.35
Ref
1.20
1.18
1.45
Ref
0.74
1.41
Ref
0.86
0.88
0.82

Ref
1.20,1.51
Ref
1.03,1.39
0.97,1.43
1.23,1.70
Ref
0.59,0.93
0.98,2.02
Ref
0.67,1.09
0.70,1.09
0.67,0.998

Ref
<.0001
Ref
0.02
0.10
<.0001
Ref
0.01
0.06
Ref
0.21
0.24
0.048
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Figure 2. Thyroid Function Testing Over Time for Adult Patients During First Known
Hospital Admission with Documentation of Heart Failure at the University of Kentucky
Albert B. Chandler Hospital from 2007-2017
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Figure 3. Specific Thyroid Function Studies Performed on Adult Patients Screened for
Thyroid Dysfunction During First Known Hospital Admission with Documentation of Heart
Failure at the University of Kentucky Albert B. Chandler Hospital from 2007-2017
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Figure 4. Thyroid Dysfunction Detected Among Those Patients Screened for Thyroid
Dysfunction During First Known Hospital Admission with Documentation of Heart Failure
at the University of Kentucky Albert B. Chandler Hospital from 2007-2017
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Figure 5. Hospitalizations Associated with Heart Failure as a Percentage of Total
Discharges at the University of Kentucky Albert B. Chandler Hospital from 2007-2017
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